Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.
Oronsky B, Goyal S, Kim MM, Cabrales P, Lybeck M, Caroen S, Oronsky N, Burbano E, Carter C, Oronsky A. Oronsky B, et al. Among authors: kim mm. Transl Oncol. 2018 Jun;11(3):771-778. doi: 10.1016/j.tranon.2018.03.014. Epub 2018 Apr 23. Transl Oncol. 2018. PMID: 29698934 Free PMC article. Review.
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA Rd, Lao CD, Abrouk NED, Fanger GR, Infante JR. Reid T, et al. Among authors: kim mm. Lancet Oncol. 2015 Sep;16(9):1133-1142. doi: 10.1016/S1470-2045(15)00089-3. Epub 2015 Aug 19. Lancet Oncol. 2015. PMID: 26296952 Clinical Trial.
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.
Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C. Carter CA, et al. Among authors: kim mm. Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr. Case Rep Oncol. 2016. PMID: 27065849 Free PMC article.
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.
Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD. Kim MM, et al. Transl Oncol. 2016 Apr;9(2):108-113. doi: 10.1016/j.tranon.2015.12.003. Transl Oncol. 2016. PMID: 27084426 Free PMC article.
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents.
Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A. Oronsky B, et al. Among authors: kim mm. Biomolecules. 2016 Jul 4;6(3):32. doi: 10.3390/biom6030032. Biomolecules. 2016. PMID: 27384589 Free PMC article. Review.
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA. Oronsky B, et al. Among authors: kim mm. Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Expert Opin Investig Drugs. 2017. PMID: 27935336 Review.
No patient left behind: The promise of immune priming with epigenetic agents.
Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR. Carter CA, et al. Among authors: kim mm. Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017. Oncoimmunology. 2017. PMID: 29123948 Free PMC article. Review.
386 results